Khellin-Derived Benzofuran-Pyrazoline Hybrids as Kinase-Targeted Anticancer Agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Khellin, a natural furochromone, serves as a versatile scaffold for developing novel therapeutic agents.
• Hybrid molecules integrating khellin derivatives with benzofuran-pyrazoline and benzofuran-pyrazoline-4-thiazolidinone moieties were designed.

Purpose of the Study:

• To synthesize and evaluate novel khellin-derived hybrid compounds for anticancer properties.
• To investigate the mechanism of action, including kinase inhibition and effects on protein expression.
• To assess the therapeutic selectivity of active compounds against cancer versus normal cell lines.

Main Methods:

• Rational design and synthesis of khellin-based hybrid compounds.
• In vitro cytotoxic assays against human breast (MCF-7) and colon (HCT116) cancer cell lines.
• Analysis of EGFR and B-RAF protein expression, kinase inhibitory activity, and selectivity profiling against normal cell lines (MCF-12A, CCD-33Co).
• Molecular docking studies to elucidate interactions with kinase ATP-binding sites.

Main Results:

• Several synthesized khellin derivatives demonstrated moderate in vitro cytotoxic activity against cancer cell lines in the micromolar range.
• Active compounds influenced EGFR and B-RAF protein levels and exhibited kinase inhibitory effects.
• Differential selectivity was observed between cancer and normal cell lines for the most potent derivatives.
• Molecular docking provided insights into the binding interactions within EGFR and B-RAF kinase active sites.

Conclusions:

• Khellin-derived benzofuran-pyrazoline hybrid systems show promise as potential anticancer agents.
• These hybrids effectively target kinases, warranting further structural optimization and mechanistic studies for therapeutic development.